COBRA Notification statement

A COBRA notification statement in insurance refers to a notice provided by employers to employees who are eligible for continued health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (COBRA).COBRA provides individuals with the option to continue their group health insurance coverage for a limited time after certain qualifying events, such as job loss or reduction in work hours.

 

Here are some key features of a COBRA notification statement:

 

·      A COBRA notification statement is a notice provided by an employer to employees who are eligible for continued health insurance coverage under COBRA.

 

·      COBRA allows individuals to continue their group health insurance coverage for a limited time after certain qualifying events, such as job loss or reduction in work hours.

 

·      The COBRA notification statement must include specific information, such as the employee's rights and responsibilities, the cost of continuing coverage, and the timeframe for electing COBRA coverage.

 

·      Employees who elect COBRA coverage must pay the full cost of the premium, plus a 2% administrative fee.

 

·      Failure to provide the required COBRA notification statement can result in penalties for the employer.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.